Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,400 shares, a growth of 39.6% from the February 13th total of 5,300 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 15,500 shares, the days-to-cover ratio is presently 0.5 days.

Bavarian Nordic A/S Stock Down 0.4 %

BVNRY stock opened at $8.07 on Tuesday. Bavarian Nordic A/S has a 12 month low of $6.86 and a 12 month high of $14.60. The firm has a 50 day moving average of $8.39 and a two-hundred day moving average of $9.61. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 11.70 and a beta of 1.83.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its earnings results on Wednesday, March 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.07. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. The firm had revenue of $299.48 million during the quarter, compared to analyst estimates of $264.06 million. On average, research analysts expect that Bavarian Nordic A/S will post 0.67 EPS for the current fiscal year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.